Key Takeaways
- Danuglipron (PF-06882961) was Pfizer's small-molecule oral GLP-1 receptor agonist
- Phase 2 data showed weight loss and HbA1c reduction but with high gastrointestinal adverse-event rates
- Pfizer discontinued the twice-daily formulation in December 2023; the once-daily modified-release version was subsequently paused
- Danuglipron is not FDA-approved and is not in active phase 3 development as of May 2026
- The discontinued status means there is no legitimate clinical or commercial supply. FormBlends does not sell or supply danuglipron
Direct answer
Danuglipron was Pfizer's investigational oral GLP-1 receptor agonist, given as a twice-daily small-molecule pill. Phase 2 trials showed meaningful weight loss and glycemic effects, but tolerability was poor: nausea and vomiting rates at therapeutic doses were unacceptably high. In December 2023, Pfizer announced discontinuation of the twice-daily formulation. The company briefly pursued a modified-release once-daily version, which was eventually paused. Danuglipron is not on a path to approval as of May 2026.
Table of contents
- The development background
- What danuglipron actually was
- Phase 2 efficacy: it worked
- Phase 2 tolerability: it didn't work well enough
- The December 2023 discontinuation
- The once-daily attempt
- How danuglipron compared to other oral GLP-1 options
- Pfizer's pivot in oral obesity drugs
- The historical significance
- The contrary view: was Pfizer too quick to walk away?
- FAQ
- Sources
The development background
Pfizer entered the GLP-1 obesity race relatively late. By the time danuglipron's phase 2 results were emerging, Wegovy was already approved and Mounjaro was about to launch. The strategic theory was that an oral pill could compete with injectables on convenience and patient preference, particularly in primary care.
Check your GLP-1 eligibility
Use our free BMI Calculator to see if you may qualify for provider-reviewed GLP-1 therapy.
Try the BMI Calculator →Danuglipron carried the Pfizer development code PF-06882961. Unlike semaglutide and other injectable GLP-1 agonists, which are peptides, danuglipron was a small molecule. Small molecules can be formulated as conventional pills with predictable absorption, unlike peptide-based oral semaglutide (Rybelsus), which requires a special absorption-enhancer formulation.
Pfizer's broader oral GLP-1 strategy also included orforglipron (PF-06954522), licensed from Lilly's program; the two companies have separate programs. (Note: orforglipron is the Lilly molecule; Pfizer's small-molecule pipeline included other compounds separately.)
What danuglipron actually was
Danuglipron was a small-molecule, orally bioavailable, partial agonist of the GLP-1 receptor. Several features made it distinct from injectable peptide GLP-1 drugs:
- Small molecule (not a peptide), allowing conventional oral formulation
- Twice-daily dosing in the original formulation
- Partial GLP-1 receptor activation, with the theoretical advantage of reduced peak effects
- Hepatic metabolism, with the potential for drug-drug interactions different from peptide drugs
The molecule itself worked. It bound the GLP-1 receptor, activated downstream signaling, produced appetite reduction and weight loss in trials. The failure was not the receptor pharmacology; it was the formulation and dosing schedule.
Phase 2 efficacy: it worked
Danuglipron phase 2 trials in type 2 diabetes and obesity reported:
- HbA1c reductions of 1.0 to 1.6 percentage points across doses (comparable to other GLP-1 class drugs)
- Mean weight loss of 5 to 9% at higher doses over 16 to 32 weeks
- Dose-dependent effects, with the highest tolerated doses producing the largest changes
For comparison: weekly injectable semaglutide 2.4 mg produces ~15% weight loss at 68 weeks. Danuglipron's 5-9% at 16-32 weeks suggested it could eventually approach 10-12% over longer durations, putting it in roughly the same class as other oral GLP-1 candidates but somewhat below the top-tier injectables.
The efficacy was respectable. It was not the problem.
Phase 2 tolerability: it didn't work well enough
The fatal issue was gastrointestinal adverse events.
Phase 2b trials reported nausea rates of 50-70% at therapeutic doses, vomiting in 20-35%, and diarrhea in 25-40%. These rates were higher than injectable semaglutide and tirzepatide. More critically, discontinuation rates due to GI adverse events were in the 30-50% range at maximum doses, which is the level at which a chronic medication becomes commercially unviable.
The likely explanation: twice-daily dosing of a small-molecule GLP-1 agonist produced sharp peak-to-trough drug exposure cycles. Each dose generated a transient peak that triggered the body's GI nausea response, which never fully attenuated because the next dose arrived 12 hours later. Injectable once-weekly drugs produce gradual exposure profiles with less peak-driven nausea.
The receptor pharmacology worked. The pharmacokinetics did not. This is a classic small-molecule drug development problem.
The December 2023 discontinuation
On December 1, 2023, Pfizer announced it was discontinuing development of the twice-daily danuglipron formulation. The press release cited tolerability concerns and the high rate of GI adverse events in phase 2 trials. Pfizer's stock dropped on the announcement.
The announcement signaled that Pfizer was not willing to attempt a phase 3 program with the twice-daily formulation. Phase 3 trials require larger patient populations over longer durations. The discontinuation rates seen in phase 2 would have produced poor adherence and outcome metrics at phase 3 scale.
Pfizer's CEO at the time, Albert Bourla, framed the decision as a portfolio reallocation: the company would focus on once-daily modified-release danuglipron and other oral obesity assets rather than chase a problematic twice-daily formulation.
The once-daily attempt
Pfizer briefly pursued a modified-release once-daily formulation of danuglipron through 2024. The hypothesis: a slower-release oral product would produce gentler exposure profiles, reducing peak nausea while maintaining efficacy.
Initial pharmacokinetic data for the once-daily version was encouraging, but subsequent disclosures during 2024-2025 indicated Pfizer paused active development. The company's stated rationale included competitive considerations (orforglipron from Lilly was further advanced) and uncertain commercial returns relative to development costs.
As of May 2026, danuglipron in any formulation is not in active phase 3 development.
How danuglipron compared to other oral GLP-1 options
| Drug | Type | Dosing | Status | Weight loss (relevant trial) |
|---|---|---|---|---|
| Rybelsus (oral semaglutide) | Peptide, special absorption tech | Once daily | FDA-approved (T2D) | ~3-4% (T2D trials) |
| Oral semaglutide 50 mg | Peptide, special absorption tech | Once daily | Investigational (OASIS program) | ~15% at 68 weeks |
| Orforglipron (Lilly) | Small molecule | Once daily | Investigational, phase 3 | ~14% at 36 weeks (phase 2) |
| Danuglipron (Pfizer) | Small molecule | Twice daily (discontinued) | Discontinued | ~5-9% at 16-32 weeks (phase 2) |
Among oral GLP-1 candidates, orforglipron is the most developed and most likely to reach FDA approval first. Oral semaglutide at the obesity dose (50 mg) is also in development. Danuglipron is no longer in the race.
Pfizer's pivot in oral obesity drugs
After the danuglipron discontinuation, Pfizer's obesity strategy reportedly shifted to:
- Acquisition or licensing of new oral obesity assets
- Research into combination products (oral GLP-1 plus other mechanisms)
- Reduced internal investment in the GLP-1 small-molecule space given competitive dynamics
Pfizer's overall presence in obesity remains modest compared to Lilly and Novo. The company has not announced a phase 3 oral obesity asset as of May 2026.
The historical significance
Danuglipron is a useful case study for understanding the obesity drug development landscape.
Lesson 1: Oral GLP-1 is hard. The peptide-based approach (Rybelsus, oral semaglutide 50 mg) requires special absorption-enhancer technology. The small-molecule approach (danuglipron, orforglipron) requires careful pharmacokinetic engineering to avoid peak-driven nausea. Both paths have produced more failures than successes.
Lesson 2: Efficacy alone is not enough. Danuglipron had reasonable efficacy. Tolerability sank it. Drug development is a multi-dimensional optimization; failing on any single dimension can end a program.
Lesson 3: Twice-daily dosing for chronic obesity therapy is a tough sell. Adherence to twice-daily regimens drops over time. Injectable once-weekly products set a high convenience bar that oral products struggle to match.
Lesson 4: Pfizer's bet didn't pay off. The company invested heavily in danuglipron based on the strategic theory that oral GLP-1 would be commercially differentiated. The execution failed. Pfizer's obesity portfolio is less competitive than projected as a result.
The contrary view: was Pfizer too quick to walk away?
The argument that Pfizer's discontinuation was premature:
Argument 1: The efficacy was real. Danuglipron worked. Reformulation could have addressed the tolerability problem without abandoning the molecule.
Argument 2: Tolerability improves with experience. GLP-1 class drugs commonly produce high GI rates in early trials that decline with refined dosing and titration protocols. A more careful phase 3 design might have rescued the program.
Argument 3: The once-daily version showed promise. The modified-release pharmacokinetics looked favorable. Pfizer paused that program prematurely.
Argument 4: Market opportunity is large. Oral GLP-1 is a large potential market. Walking away from it after one formulation failure reduces Pfizer's strategic position.
The counterargument: Pfizer had the data and the development team to make the call. Phase 3 obesity trials cost hundreds of millions of dollars. Starting one with a known tolerability problem is a high-cost bet. Pfizer's decision to redirect investment was financially defensible, even if it left the obesity portfolio underweight.
Decision framework
If you are a patient seeking an oral GLP-1 option: Rybelsus (FDA-approved for T2D) is the legitimate option today. Oral semaglutide 50 mg for obesity is in development. Orforglipron is in phase 3. Danuglipron is not an option.
If you encounter "danuglipron" sold online: the product is not the clinical drug. The molecule is not commercially manufactured. Whatever is being sold under that name has unknown identity and quality.
If you are evaluating Pfizer's obesity strategy: the danuglipron story is a worked example of execution risk in drug development. Pfizer remains in obesity but with a smaller portfolio than peers.
If you are interested in the science: the danuglipron story illustrates the difficulty of translating a working receptor pharmacology into a viable formulation. The molecule worked at the target level; the drug product did not work as a chronic therapy.
FAQ
How do you pronounce danuglipron?
Approximately "dan-yoo-GLIP-ron."
Is danuglipron the same as Ozempic?
No. Ozempic is injectable semaglutide. Danuglipron was Pfizer's discontinued oral small molecule.
Why is danuglipron discontinued?
Phase 2 tolerability problems and competitive considerations led Pfizer to halt twice-daily development in December 2023 and subsequently pause the once-daily program.
Will danuglipron come back?
No announced plans as of May 2026.
Was danuglipron approved by the FDA?
No. It never reached FDA review.
Did danuglipron work?
Yes, in the sense of producing measurable weight loss and HbA1c reduction. Tolerability was the issue, not pharmacology.
How much weight did people lose on danuglipron?
Phase 2 trials reported 5-9% at higher doses over 16-32 weeks. Modest compared to injectable options.
Can I buy danuglipron from China?
The molecule is not approved in China either. Online vendors selling "danuglipron" are not selling the Pfizer clinical product.
Is danuglipron the same as orforglipron?
No. Different molecules, different developers. Orforglipron is Lilly's once-daily oral GLP-1 in phase 3.
What replaced danuglipron at Pfizer?
Pfizer's obesity portfolio has not announced a replacement asset of comparable visibility.
Is the discontinuation final?
Drug development decisions can change. As of May 2026, danuglipron is not on a path to approval.
Related guides
- Why Was Danuglipron Discontinued? Pfizer's Walk-Away from the Oral GLP-1 Race
- What Is Orforglipron? Lilly's Oral GLP-1 Pill, Explained
- Oral vs Injectable GLP-1: Why a Pill Took So Long to Make
Sources
- Pfizer Inc. Press Release: Pfizer Provides Update on Phase 2 Studies of Lead Oral GLP-1 Receptor Agonist, Danuglipron. December 1, 2023.
- Saxena AR et al. Danuglipron in patients with type 2 diabetes: a phase 2b randomized, double-blind, placebo-controlled trial. JAMA Network Open or comparable. 2023.
- Pfizer R&D Day Materials and Investor Disclosures. 2023-2024.
- Bays HE et al. The Pharmacotherapy of Obesity. Endocrine Reviews. 2023.
- FDA. Rybelsus (Oral Semaglutide) Prescribing Information. 2024 revisions.
- Wharton S et al. Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity (phase 2). NEJM. 2023.
- Knop FK et al. Oral semaglutide 50 mg taken once a day in adults with overweight or obesity (OASIS 1). Lancet. 2023.
- Aroda VR et al. Efficacy and safety of once-daily oral semaglutide in patients with type 2 diabetes (PIONEER program). Diabetes Care. 2019-2022.
- Endocrine Society. Pharmacological Management of Obesity Clinical Practice Guideline. 2024 update.
- STAT News, Reuters, and Bloomberg coverage of Pfizer obesity strategy and danuglipron development. 2023-2024.
Footer disclaimers
Platform Disclaimer. FormBlends is a telehealth platform connecting patients with independent licensed clinicians and pharmacies. We do not manufacture, dispense, or supply danuglipron or any discontinued investigational compound. Clinical care is provided by independent prescribers.
Discontinued Drug Notice. Danuglipron is a discontinued investigational compound. It is not FDA-approved, never reached commercial sale, and is not being actively developed for approval as of May 2026. Online vendors using the name "danuglipron" are not selling the Pfizer clinical product.
Results Disclaimer. Phase 2 efficacy results cited reflect group means in controlled trial settings. The drug never reached phase 3, so no large-trial efficacy or safety data is available. Real-world outcomes were never accumulated because the drug never launched.
Trademark Notice. Danuglipron is the generic name of the Pfizer development compound. Rybelsus, Wegovy, and Ozempic are registered trademarks of Novo Nordisk A/S. Mounjaro and Zepbound are registered trademarks of Eli Lilly and Company. FormBlends is not affiliated with Pfizer Inc., Novo Nordisk, or Eli Lilly.
See your options in about 2 minutes
Take the free quiz and see what fits you. Quick, private, and no commitment to continue.
See my options →